Home > Insider Trading > Filing (0001689813-19-000097)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1262325	Eric Aguiar	C/O Aisling Capital Llc 888 Seventh Avenue, 12Th Floor New York NY 10106		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2019-11-20	6,729	$32.42	6,729	No	4	M	Indirect	By Spouse
Common Shares	Disposition	2019-11-20	6,729	$52.20	0	No	4	S	Indirect	By Spouse
Common Shares	Acquisiton	2019-11-22	1,250	$37.54	1,250	No	4	M	Indirect	By Spouse
Common Shares	Disposition	2019-11-22	1,250	$55.24	0	No	4	S	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	M	Indirect	By Spouse
No	4	S	Indirect	By Spouse

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2019-11-20	6,729	$0.00	6,729	$32.42
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2019-11-22	1,250	$0.00	1,250	$37.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
23,271		2028-11-19	No	4	M	Indirect
3,750		2027-09-04	No	4	M	Indirect

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.31 - $53.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the Reporting Person's spouse continuous service with the issuer at each vesting date.
The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the Reporting Person's spouse continuous service with the issuer at each vesting date.